ReportGem ReportGem EN

普通外文研报

Shrinking to Grow Series: GLP-1 / Apparel Monthly Update

发布日期: 2026-06-05研究机构: Wells Fargo Securities, LLC报告页数: 7原文语言: 英语证据页码: 1

研报英文原文证据摘录

Shrinking to Grow Series: GLP-1 / Apparel Monthly Update

Equity Research

Industry Update — June 5, 2026

Retailing, Specialty Softlines, and E-commerce

Shrinking to Grow Series: GLP-1 / Apparel

Monthly Update

Industry Data Points and Thoughts Post May

Our Call Ike Boruchow

The GLP-1 apparel cycle continues: 1) Apparel spend remains above historical trend, Equity Analyst | Wells Fargo Securities, LLC Ike.Boruchow@wellsfargo.com | 212-214-8024

2) Script data is accelerating, 3) GLP US search interest still > 2x LY, 4) Companies now

Paul Kearneyspeaking to impact and 5) Apparel continues to outperform athletic/footwear.

Associate Equity Analyst | Wells Fargo Securities, LLC

Paul.D.Kearney@wellsfargo.com | 212-214-4837

GLP-1/Apparel Update. We continue to believe we are in the early- to mid-innings of a Juliana Duque

GLP-1 driven fit-cycle in apparel. New modalities continue to drive adoption, barriers are Associate Equity Analyst | Wells Fargo Securities, LLC

coming down and costs are making weight-loss drugs more accessible. Full details on our Juliana.Duque@wellsfargo.com | 305-329-6767

April note can be found here: Shrinking to Grow: GLP-1s Set to Fuel a Multi-Year Fit Cycle in Robert Bischoff

Apparel. With this update, we highlight recent news and track the most critical KPIs. Associate Equity Analyst | Wells Fargo Securities, LLC

Robert.Bischoff@wellsfargo.com | 305-329-6777

Key Updates. 1) New data on the effectiveness of retatrutide achieves weight loss in

patients on-par with bariatric surgery; 2) EU approval of the Wegovy pill expands the

benefit internationally, 3) Highlighting WFS work that insurance coverage continues to be

a major opportunity for future adoption (Breaking the Bottleneck: How Carve-Outs Could

本摘录由系统从所标注的 PDF 证据页直接提取并保留英文原文,不做批量翻译;登录后在阅读器切换中文时才按需翻译。

打开研报阅读器